DCV Technologies Inc produces vaccines derived from technology that encompasses the identification and description of the display of proteolytic activity (proteases) on the surface of tumor cells as a result of the carcinogenic process. This technology offers candidate secretory genes that are overexpressed in ovarian carcinoma, and seldom expressed in normal adult tissues as diagnostic markers for ovarian carcinoma, and as targets for therapeutic intervention in growth and spread of ovarian tumor cells. The production of large volumes of antibodies in transgenic plants is the most likely source of drugs to inhibit the spread of these cancers
